Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
October 3, 2017
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Inventors:
Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
Abstract: The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.
Type:
Grant
Filed:
November 11, 2009
Date of Patent:
September 26, 2017
Assignee:
The Procter & Gamble Company
Inventors:
Douwe Van Sinderen, Jun Xu, Wenzhu (Steven) Zhao, Raymond A. Grant, Song Yuli, Charles Bascom, Duane Larry Charbonneau, Liam O'Mahony
Abstract: The genetic basis for severe combined immunodeficiency disease (SCID) in pigs is described. In addition, tests for detecting pigs that are carriers for SCID or pigs with SCID are also described. Further, methods for producing pigs or herds of pigs with SCID are also described. Further, methods and compositions for treating, ameilioraing, inhibiting or correcting SCID are provided.
Type:
Grant
Filed:
January 8, 2015
Date of Patent:
August 29, 2017
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Jack C. M. Dekkers, Christopher K. Tuggle, Emily H. Waide, Jason W. Ross, N. Matthew Ellinwood, Martine Schroyen
Abstract: This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.
Type:
Grant
Filed:
January 13, 2011
Date of Patent:
August 29, 2017
Assignee:
Cornell University
Inventors:
Laurie H. Glimcher, Dallas C. Jones, Marc Wein
Abstract: The present invention relates to the identification of p53 biomarker profiles that predict response in patients with hyperproliferative disease such as cancer to a therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy.
Abstract: Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
August 15, 2017
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Shivalingappa Kottur Swamynathan, Sudha Swamynathan, Kristine-Ann Gallegos Buela, Robert Lee Hendricks
Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or Inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
Type:
Grant
Filed:
October 7, 2016
Date of Patent:
July 25, 2017
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
Abstract: Disclosed herein are genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
Abstract: Reagents and methods are provided that allow for an improved expression of a recombinant protein in an insect, More specifically, the introduction of recombinant DNA elements into an insect larva allows for the increased expression of a recombinant protein, an improvement of the correct folding of said protein and an increase in the survival rate after infection of the insect These recombinant DNA elements can be introduced, for example, into insect larvae via a recombinant baculovirus, which has incorporated said elements. The recombinant DNA elements include nucleic acids encoding transcriptional regulators, such as IE-0 and IE-1, transcriptional, enhancer elements, such as the homologous region (hr) and promoters.
Type:
Grant
Filed:
June 12, 2012
Date of Patent:
July 11, 2017
Assignee:
ALTERNATIVE GENE EXPRESSION S.L.
Inventors:
Silvia Gomez Sebastian, Javier López Vidal, José Angel Martinez Escribano
Abstract: The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
December 12, 2013
Date of Patent:
June 27, 2017
Assignee:
NOVOZYMES, INC.
Inventors:
Suzanne Otani, Haiyan Ge, Paul Harris, Debbie Yaver, Alexander Blinkovsky
Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
Type:
Grant
Filed:
December 19, 2013
Date of Patent:
June 27, 2017
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy
Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Type:
Grant
Filed:
April 12, 2016
Date of Patent:
June 6, 2017
Assignee:
The Regents of the University of California
Inventors:
Wendell A. Lim, Leonardo Morsut, Kole T. Roybal
Abstract: The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.
Type:
Grant
Filed:
May 12, 2015
Date of Patent:
June 6, 2017
Assignee:
DSM IP Assets B.V.
Inventors:
Kirk E. Apt, Paul Warren Behrens, Jon Milton Hansen, Joseph W. Pfeifer, III, Tracey Lynn Stahl, Ross Zirkle
Abstract: Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.
Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.
Type:
Grant
Filed:
August 20, 2014
Date of Patent:
April 18, 2017
Assignee:
Advangen International Pty Ltd
Inventors:
Sadatoshi Sakuma, Maria Halasz, Darren Jones
Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
Type:
Grant
Filed:
October 26, 2012
Date of Patent:
April 11, 2017
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
Abstract: The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.
Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
March 14, 2017
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lynn MacDonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue